Clinical Trials Browser

Phase 3 × Dermatologic × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT06568172 2026-03-18

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Recruiting

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT02821013 2026-03-10

STOP-GAP

Phase 3 Recruiting

Melanoma

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT07144345 2026-03-05

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

Phase 3 Active not recruiting

DermatologicOther neoplasm

Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT06246149 2026-03-04

ATOM

Phase 3 Recruiting

Uveal Melanoma

NCT06007690 2026-03-02

CoMpass

Phase 3 Recruiting

Uveal Melanoma, Eye Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 1 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT05907122 2026-02-27

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Phase 3 Completed

Melanoma

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Melanoma

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 3 Recruiting

Melanoma, Nevus, Blue

NCT06585410 2026-02-25

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Phase 3 Recruiting

Skin Neoplasms

NCT06587451 2026-02-24

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Phase 3 Terminated

Melanoma

NCT07144852 2026-02-20

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Phase 3 Active not recruiting

DermatologicOther neoplasm

Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT05662202 2026-02-19

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Phase 3 Active not recruiting

Keratosis, Actinic

NCT06246916 2026-02-19

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Phase 3 Recruiting

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Phase 3 Active not recruiting

267 enrolled 8 charts

Melanoma

NCT07015190 2026-02-18

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Phase 3 Recruiting

Uveal Melanoma, Melanoma

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT07381972 2026-02-02

Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma

Phase 3 Recruiting

Nodular Basal Cell Carcinoma of Skin

NCT05212246 2026-01-22

B3C

Phase 3 Not yet recruiting

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Patient Compliance, Keratosis, Actinic

NCT06135415 2026-01-22

TirbAKare

Phase 3 Completed

DermatologicOther neoplasm

Keratosis, Neoplasms, Precancerous Conditions, Keratosis, Actinic

NCT06500455 2026-01-14

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Phase 3 Recruiting

BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06054555 2026-01-12

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma

NCT05002569 2026-01-08

RELATIVITY-098

Phase 3 Terminated

1,093 enrolled 15 charts

Melanoma

NCT07311070 2026-01-06

Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue

Phase 3 Enrolling by invitation

Carcinoma, Basal Cell

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT00799188 2025-12-19

CERTICOEUR

Phase 3 Completed

Skin Neoplasms

NCT03567889 2025-12-17

NeoDREAM

Phase 3 Recruiting

Melanoma

NCT06794775 2025-12-12

SWE-NEO

Phase 3 Recruiting

Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05522660 2025-12-11

USZ-STRIKE

Phase 3 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07273656 2025-12-09

TIRBACRYO

Phase 3 Not yet recruiting

Keratosis, Keratosis, Actinic

NCT06470451 2025-11-14

FLASH2

Phase 3 Recruiting

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT07068074 2025-11-13

A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients

Phase 3 Not yet recruiting

Melanoma

NCT01223248 2025-11-04

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Phase 3 Active not recruiting

DermatologicGynecologicSarcoma

Melanoma, Ovarian Neoplasms, Sarcoma, Pyloric Stenosis, Hypertrophic

NCT01546571 2025-10-24

MAVIS

Phase 3 Terminated

504 enrolled 23 charts

Melanoma

NCT05665595 2025-10-15

KEYVIBE-010

Phase 3 Completed

1,594 enrolled 12 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04341064 2025-10-14

SHINE

Phase 3 Completed

Skin Neoplasms

NCT06050122 2025-10-14

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Phase 3 Active not recruiting

Basal Cell Nevus Syndrome

NCT04674683 2025-09-24

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Phase 3 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05933577 2025-09-24

V940-001

Phase 3 Active not recruiting

Melanoma

NCT03969004 2025-09-19

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 1 FDA

Cutaneous Squamous Cell Carcinoma

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT03271372 2025-09-17

ADAM

Phase 3 Active not recruiting

Carcinoma, Merkel Cell

NCT07178457 2025-09-17

BeCALM

Phase 3 Not yet recruiting

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT05860881 2025-09-09

SiroSkin

Phase 3 Active not recruiting

Skin Neoplasms

NCT05155254 2025-08-28

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Phase 3 Active not recruiting

Melanoma